Beacon Hospital Contributes to Landmark ARIA Study on First-Line Dacomitinib in EGFR-Mutated Lung Cancer

Beacon Hospital is proud to announce the publication of the final analysis of the ARIA study, a landmark international real-world investigation evaluating the outcomes of first-line dacomitinib in 299 patients with epidermal growth factor receptor (EGFR)–mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). The efforts in Beacon Hospital were headed by Dr Tho Lye Mun, Consultant Clinical Oncologist, with the assistance of Beacon Hospital’s Cancer Clinical Research department.

NSCLC accounts for approximately 85% of all lung cancer cases. Advances in molecular testing have identified EGFR-activating mutations as key drivers of disease, leading to the development of targeted EGFR tyrosine kinase inhibitors (TKIs). These therapies have transformed lung cancer treatment and are now established as standard first-line therapy for EGFR mutation–positive NSCLC.

“As clinicians, real-world data are essential in understanding how therapies perform outside clinical trial settings,” said Dr Tho. “The ARIA is the largest real-world study providing valuable insights into the use of first-line dacomitinib in routine practice and supports its clinical effectiveness in Asian patients with EGFR mutation–positive advanced NSCLC.”

Beacon Hospital remains committed to advancing cancer research and improving patient outcomes through meaningful participation in high-impact international clinical studies.